Compare · ILMN vs MSON
ILMN vs MSON
Side-by-side comparison of Illumina Inc. (ILMN) and MISONIX, Inc. (MSON): market cap, price performance, sector, and recent activity on the wire.
Summary
- ILMN operates in Health Care, while MSON operates in Capital Goods - the two are in different parts of the market.
- ILMN is the larger of the two at $19.43B, about 42.0x MSON ($462.5M).
- ILMN has hit the wire 5 times in the past 4 weeks while MSON has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 2 for MSON).
- Company
- Illumina Inc.
- MISONIX, Inc.
- Price
- $127.93+2.01%
- $26.23+3.72%
- Market cap
- $19.43B
- $462.5M
- 1M return
- +1.37%
- -
- 1Y return
- +65.69%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 1992
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 2
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
MISONIX, Inc.
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator, which is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system that provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
Latest ILMN
- DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
- Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
- Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
- SEC Form DEFA14A filed by Illumina Inc.
- SEC Form DEF 14A filed by Illumina Inc.
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Meister Keith A.
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Illumina Announces Changes to Board of Directors
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
Latest MSON
- SEC Form 4: Koby Michael returned 1,744,017 shares to the company
- SEC Form 4: Vizirgianakis Stavros G. returned 2,136,478 shares to the company, closing all direct ownership in the company
- SEC Form 4: Patton Thomas M returned 104,500 shares to the company, closing all direct ownership in the company
- SEC Form 4: Ludecker Robert S returned 319,443 shares to the company, closing all direct ownership in the company
- SEC Form 4: Laviolette Paul A returned 1,744,017 shares to the company
- SEC Form 4: Dwyer Joseph P returned 276,200 shares to the company, closing all direct ownership in the company
- SEC Form 4: Beyer Pat returned 20,000 shares to the company, closing all direct ownership in the company
- SEC Form RW filed by MISONIX, Inc.
- SEC Form 15-12B filed by MISONIX, Inc.
- MISONIX, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits